Potentially protein-destabilizing C3 polymorphism in a case of atypical hemolytic uremic syndrome with life-threatening extrarenal manifestations
Authors:
- Takuji EnyaTETakuji Enya
- Kohei MiyazakiKMKohei Miyazaki
- Yuichi MorimotoYMYuichi Morimoto
- Hiroki KondouHKHiroki Kondou
- Naoki SakataNSNaoki Sakata
- Kensuke JohKJKensuke Joh
- China NaganoCNChina Nagano
- Nobutoshi ItoNINobutoshi Ito
- Yoshiyuki HakataYHYoshiyuki Hakata
- Masaaki MiyazawaMMMasaaki Miyazawa
- Keisuke SugimotoKSKeisuke Sugimoto
Preprint
- 31 October 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening disease caused by uncontrolled complement activation. It is frequently associated with a genetic factor including various polymorphisms at the C3 gene locus; however, no functional amino acid substitution in the C-terminal domain has been reported. We experienced a pediatric case of aHUS with multisystem involvements including refractory hypertension and gastrointestinal bleeding in which immunohistochemical, genetic, and molecular structural analyses were performed. Methods: Biopsy specimens were stained for renin and C5b-9. Serum factor Ba levels were measured to evaluate the alternative pathway activation. Genomic DNA was obtained with consent for targeted Sanger sequencing. The possible effects of the identified amino acid substitution on the molecular structure of C3 were analyzed by computer-aided simulation. Results: Immunostaining revealed intense renin staining in the hyperplastic juxtaglomerular apparatus. Endothelial cells of renal and intestinal blood vessels were positive for C5b-9. Serum Ba level in the active phase was higher than control level. Genetic analyses showed a C3 polymorphism resulting in M1604T substitution in the C345C domain. Although previously reported to be a variant of unknown significance, molecular structural analysis indicated that this amino acid substitution results in the formation of a large space within the hydrophobic core of the C-terminal domain, possibly destabilizing the spherical structure of C3. Renin-angiotensin system inhibitors for refractory hypertension were effective in this patient. Conclusions: M1604T substitution in the C345C domain of C3 molecule may functionally underlie the observed life-threatening extrarenal manifestations.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene AbnormalityKidney International Reports, 2021
- Extra-Renal manifestations of atypical hemolytic uremic syndrome in childrenPediatric Nephrology, 2018
- Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndromeClinical and Experimental Nephrology, 2018
- Comparative Protein Structure Modeling Using MODELLERCurrent Protocols in Bioinformatics, 2016
- The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathyJournal of the American Society of Hypertension, 2016
- Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertensionPediatric Nephrology, 2014
- An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndromePediatric Nephrology, 2014
- Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristicsPediatric Nephrology, 2012
- Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathwayBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- Engineering of human complement component C3 for catalytic inhibition of complementImmunology Letters, 2005